These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Serum levels of sFas and sFasL during chemotherapy of lung cancer. Naumnik W; Izycki T; Ossolinska M; Chyczewska E Exp Oncol; 2007 Jun; 29(2):132-6. PubMed ID: 17704746 [TBL] [Abstract][Full Text] [Related]
5. Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors. Kondera-Anasz Z; Mielczarek-Palacz A; Sikora J Apoptosis; 2005 Oct; 10(5):1143-9. PubMed ID: 16151647 [TBL] [Abstract][Full Text] [Related]
6. Soluble fas antigen and soluble fas ligand in intrauterine growth restriction. Briana DD; Baka S; Boutsikou M; Liosi S; Vraila VM; Gourgiotis D; Hassiakos D; Malamitsi-Puchner A Neonatology; 2010; 97(1):31-5. PubMed ID: 19590243 [TBL] [Abstract][Full Text] [Related]
7. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients. Erdoğan B; Uzaslan E; Budak F; Karadağ M; Ediger D; Oral B; Göral G; Ege E; Gözü O Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648 [TBL] [Abstract][Full Text] [Related]
8. Elevated serum soluble Fas ligand is a promising marker of testicular toxicity induced by epirubicin in rats. Geng J; Fan J; Jiang HW; Fang ZJ; Wang X; Sun JL; Ding Q; Chen G Toxicol Lett; 2009 Apr; 186(2):96-103. PubMed ID: 19429229 [TBL] [Abstract][Full Text] [Related]
9. [Change in serum levels of soluble Fas and soluble FasL in patients with multiple organ dysfunction syndrome]. Fu Y; Xiao QM; Wang T; Chen XH; Ai YH Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2006 Nov; 18(11):691-4. PubMed ID: 17092425 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the maternal and umbilical vein serum sFas/sFasL system in pregnancies complicated by preeclampsia with intrauterine growth retardation. Laskowska M; Laskowska K; Leszczyńska-Gorzelak B; Oleszczuk J Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):155-9. PubMed ID: 16169656 [TBL] [Abstract][Full Text] [Related]
11. Serum and follicular fluid levels of soluble Fas and soluble Fas ligand in IVF cycles. Onalan G; Selam B; Onalan R; Ceyhan T; Cincik M; Pabuccu R Eur J Obstet Gynecol Reprod Biol; 2006 Mar; 125(1):85-91. PubMed ID: 16140454 [TBL] [Abstract][Full Text] [Related]
12. [Levels and clinic significance of serum soluble Fas and soluble Fas ligand in coal workers' pneumoconiosis]. Yuan BJ; Liu ZZ; Ding XR; Zou JM Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2006 Feb; 24(2):96-8. PubMed ID: 16600114 [TBL] [Abstract][Full Text] [Related]
13. Upregulation of the sFas/sFasL system in psoriatic patients. Myśliwiec H; Baran A; Myśliwiec P; Górska M; Flisiak I Adv Med Sci; 2015 Mar; 60(1):64-8. PubMed ID: 25437350 [TBL] [Abstract][Full Text] [Related]
14. Serum sFas/sFasL ratio in systemic lupus erythematosus (SLE) is a function of age. Turi MC; D'Urbano M; Celletti E; Alessandri C; Valesini G; Paganelli R Arch Gerontol Geriatr; 2009; 49 Suppl 1():221-6. PubMed ID: 19836636 [TBL] [Abstract][Full Text] [Related]
15. Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST. Blanco-Colio LM; Martín-Ventura JL; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Martineau P; Hérnandez G; Egido J; Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):168-74. PubMed ID: 17053166 [TBL] [Abstract][Full Text] [Related]
16. The sFas/sFasL ratio as a novel marker of inflammation in children with chronic kidney disease. Musiał K; Zwolińska D Clin Chim Acta; 2012 Dec; 414():7-11. PubMed ID: 22898262 [TBL] [Abstract][Full Text] [Related]
17. [Clinical significances of serum soluble fas and soluble fas ligand in chronic hepatitis B]. Jun EJ; Han JY; Sun HS Korean J Hepatol; 2006 Dec; 12(4):507-14. PubMed ID: 17237628 [TBL] [Abstract][Full Text] [Related]
18. Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF. Onalan G; Selam B; Baran Y; Cincik M; Onalan R; Gündüz U; Ural AU; Pabuccu R Hum Reprod; 2005 Sep; 20(9):2391-5. PubMed ID: 15932917 [TBL] [Abstract][Full Text] [Related]
19. sFas and sFas ligand and pediatric sepsis-induced multiple organ failure syndrome. Doughty L; Clark RS; Kaplan SS; Sasser H; Carcillo J Pediatr Res; 2002 Dec; 52(6):922-7. PubMed ID: 12438671 [TBL] [Abstract][Full Text] [Related]
20. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment. Tinazzi E; Puccetti A; Gerli R; Rigo A; Migliorini P; Simeoni S; Beri R; Dolcino M; Martinelli N; Corrocher R; Lunardi C Int Immunol; 2009 Mar; 21(3):237-43. PubMed ID: 19181929 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]